These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They ...

Oral semaglutide administered via the RaniPill® HC (RT-116) demonstrated comparable bioavailability, pharmacokinetics and ...

SAN JOSE, Calif. - Rani Therapeutics Holdings , Inc. (NASDAQ:RANI), a clinical-stage biotherapeutics company with a market capitalization of $48.3 million, today announced promising results from a ...

On Friday, H.C. Wainwright adjusted its outlook on shares of Rani Therapeutics Holdings (NASDAQ:RANI), reducing the 12-month price target to $9 from the previous $13, while ...

Investing.com - Rani Therapeutics Holdings reported on Thursday third quarter earnings that beat analysts' forecasts and revenue that fell short of expectations. Rani ...

After hours: February 3 at 5:13:48 PM EST Loading Chart for RANI ...

1 Day RANI 0.72% DJIA -0.75% Russell 2K -0.86% Health Care/Life Sciences 0.29% ...

Results of the first human study of a capsule designed to replace injections of biologics have been announced, using an automatic pill designed by Silicon Valley-based Rani Therapeutics.